••
Kintampo Health Research Centre begins Lassa fever vaccine trial
•2 min read•1 source
Ghana has officially launched clinical trials for the ChAdOx1 LassaJ vaccine, an experimental shot designed to combat Lassa fever. The trials, which commenced on October 14, are being conducted at the Kintampo Health Research Centre (KHRC) in the Bono East Region. This critical research phase aims to evaluate the safety of the vaccine and the immune responses it triggers in human participants, marking a significant step in regional efforts to control the viral hemorrhagic illness.
The study involves up to 51 healthy adult volunteers who will be closely monitored by researchers at the facility. Developed by the University of Oxford and supported by the Coalition for Epidemic Preparedness Innovations (CEPI), the vaccine represents a collaborative international effort to address a disease that remains endemic in several West African nations. Although Ghana is not currently experiencing a Lassa fever outbreak, the Director of the Kintampo Health Research Centre emphasized that the research is essential for national and regional public health security.
The trial is particularly relevant given the high volume of travel and trade between Ghana and Nigeria, where Lassa fever outbreaks are a regular occurrence. Scientists believe that a successful vaccine could drastically reduce the high mortality rates and the heavy economic burden associated with the disease across the sub-region. If the ChAdOx1 LassaJ shot proves safe and effective in these early phases, it could eventually become a cornerstone of preventative healthcare strategies in West Africa, offering a long-awaited defense against a persistent health threat.
